XORTX Therapeutics Inc
Research XORTX Therapeutics Inc (XRTX) on Bullrun: market cap USD 3.15M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerXRTX
- ExchangeNASDAQ
- CountryCanada
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 3.15M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 808.47K
- Free cash flow-USD 505.15K
Valuation Snapshot
latest market cap is USD 3.15M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 2.66M | -USD 2.82M | n/a | -5.35 | USD 864.51K | USD 37.29K | USD 2.08M |
| FY2024 | USD 0 | -USD 3.31M | -USD 3.72M | n/a | n/a | USD 2.47M | USD 38.79K | USD 3.34M |
| FY2023 | n/a | n/a | n/a | n/a | -3.56 | USD 3.45M | USD 11.51K | USD 4.64M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 3.15M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 3.91M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 3.93M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 4.62M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 109.30M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 239.69M | n/a | n/a | n/a |
About XORTX Therapeutics Inc
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is XORTX Therapeutics Inc's market cap?
XORTX Therapeutics Inc's market capitalization is USD 3.15M.
What does XORTX Therapeutics Inc do?
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada.